Myfortic (Mycophenolic Acid)

Mycophenolic acid, the active ingredient in Myfortic, is an antimetabolite presented as a delayed‑release tablet for oral use. It is used to prevent organ rejection in kidney and other solid organ transplant recipients.

GNH USA supplies Myfortic as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Myfortic, an antimetabolite immunosuppressant, is used in transplantation to inhibit lymphocyte proliferation.

Kidney transplantation: helps prevent acute and chronic rejection of the transplanted kidney. Other solid organ transplantation (e.g., liver, heart, lung): reduces the risk of graft rejection. Pancreas transplantation: lowers the incidence of pancreas graft rejection.

Myfortic may cause a range of adverse reactions. Patients should be aware of both frequent and less common events.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Diarrhea: loose stools that may affect hydration. - Vomiting: occasional emesis. - Abdominal pain: discomfort in the stomach area. - Headache: transient cranial pain. - Dyspepsia: indigestion or heartburn.

Serious or Rare Side Effects: - Leukopenia: significant drop in white blood cells. - Anemia: reduced red blood cell count. - Severe infections: opportunistic bacterial, viral or fungal infections. - Hepatic dysfunction: abnormal liver enzyme elevations. - Malignancy: increased risk of certain cancers. - Progressive multifocal leukoencephalopathy (PML): rare but serious brain infection.

Before initiating Myfortic, clinicians should consider several safety measures.

Monitor blood counts: perform regular CBC to detect leukopenia or anemia. Assess renal function: adjust therapy if kidney impairment is present. Screen for infections: watch for opportunistic or viral infections. Avoid in pregnancy: discuss contraception due to potential teratogenic risk. Store at ambient temperature: keep below 25°C, protect from moisture and retain in original packaging.

Myfortic can interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Cyclosporine: may increase mycophenolic acid exposure; monitor levels. - Tacrolimus: similar risk of heightened exposure. - Strong CYP3A4 inhibitors (e.g., ritonavir): can raise drug concentrations. - Live vaccines: heightened risk of infection; avoid concurrent use.

Moderate Interactions (Monitor Closely): - Antacids or cholestyramine: may reduce absorption of mycophenolic acid. - Azathioprine: additive bone‑marrow suppression potential. - Non‑live vaccines: monitor immune response effectiveness.